Cite
APA Citation
Heinen, A., Schnabel, A., Brück, N., Smitka, M., Wolf, C., Lucas, N., Dollinger, S., Hahn, G., Günther, C., Berner, R., Lee-Kirsch, M., & Schuetz, C. (2021). interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?. Rheumatology, 60, e136–e138. http://access.bl.uk/ark:/81055/vdc_100124372737.0x000026